Compound glutamine enteric-coated capsules in the treatment and prevention of radiotherapy- and chemotherapy-related intestinal dysfunction in patients with malignant tumors: a systematic review
|更新时间:2026-04-24
|
Compound glutamine enteric-coated capsules in the treatment and prevention of radiotherapy- and chemotherapy-related intestinal dysfunction in patients with malignant tumors: a systematic review
CHEN Yuxian,ZOU Dan,HU Qiaozhi.Compound glutamine enteric-coated capsules in the treatment and prevention of radiotherapy- and chemotherapy-related intestinal dysfunction in patients with malignant tumors: a systematic review[J].ZHONGGUO YAOFANG,2026,37(08):1068-1073.
CHEN Yuxian,ZOU Dan,HU Qiaozhi.Compound glutamine enteric-coated capsules in the treatment and prevention of radiotherapy- and chemotherapy-related intestinal dysfunction in patients with malignant tumors: a systematic review[J].ZHONGGUO YAOFANG,2026,37(08):1068-1073. DOI: 10.6039/j.issn.1001-0408.2026.08.17.
Compound glutamine enteric-coated capsules in the treatment and prevention of radiotherapy- and chemotherapy-related intestinal dysfunction in patients with malignant tumors: a systematic review
To evaluate the efficacy of Compound glutamine enteric-coated capsules in the treatment and prevention of radiotherapy- and chemotherapy-related intestinal dysfunction in patients with malignant tumors.
METHODS
2
PubMed, Embase, CNKI, and Wanfang data were searched to collect randomized controlled trial (RCT) and cohort studies comparing Compound glutamine enteric-coated capsules (experimental group) with or without other treatments versus other treatments or blank control (control group). The search period was from the establishment of each database to November 19, 2025. After literature screening, data extraction, and quality assessment, a meta-analysis was performed using RevMan 5.4 software.
RESULTS
2
A total of 23 studies were included, involving 2 014 patients. Meta-analysis results showed that the effective rate in the experimental group was significantly higher than that in the control group, the overall incidence and moderate-to-severe incidence of radiotherapy- and chemotherapy-related intestinal dysfunction, quality of life scores, and interleukin-6 levels in the experimental group were significantly lower than those in the control group (
P
<0.05). However, no statistically significant differences were observed between the two groups in terms of Karnofsky Performance Status score improvement rate and tumor necrosis factor-α levels (
P
>0.05). The results of subgroup analysis based on different medications in the control group showed that, when used for treatment, regardless of whether patients in the control group received blank control or positive control, the efficacy in the experimental group was significantly higher than that in the control group (
P
<0.05). When used for prevention, compared with patients who received blank control in the control group, the overall incidence and the incidence of moderate-to-severe radiotherapy- and chemotherapy-related intestinal dysfunction in the experimental group were significantly reduced (
P
<0.05). No statistically significant difference was found in the overall incidence or incidences of moderate-to-severe radiotherapy- and chemotherapy-related intestinal dysfunction with positive control between the two groups (
P
>0.05).
CONCLUSIONS
2
Compound glutamine enteric-coated capsules can effectively treat and prevent radiotherapy- and chemotherapy-related intestinal dysfunction in patients with malignant tumors, improve patients’ quality of life, and alleviate inflammatory responses.
关键词
Keywords
references
THOMSEN M , VITETTA L . Adjunctive treatments for the prevention of chemotherapy-and radiotherapy-induced mucositis [J ] . Integr Cancer Ther , 2018 , 17 ( 4 ): 1027 - 1047 .
PETERSON D E , BOERS-DOETS C B , BENSADOUN R J , et al . Management of oral and gastrointestinal mucosal injury:ESMO clinical practice guidelines for diagnosis,treatment,and follow-up [J ] . Ann Oncol , 2015 , 26 ( Suppl. 5 ): v 139-v151.
ANDERSON P M , LALLA R V . Glutamine for amelioration of radiation and chemotherapy associated mucositis during cancer therapy [J ] . Nutrients , 2020 , 12 ( 6 ): 1675 .
U.S. Department of Health and Human Services , National Institutes of Health , National Cancer Institute . Common Terminology Criteria for Adverse Events(CTCAE)Version 5.0 [EB/OL ] .( 2017-11-27 )[ 2026-03-19 ] . https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50 https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50 .
HIGGINS J P T , THOMAS J , CHANDLER J , et al . Cochrane handbook for systematic reviews of interventions version 6.5 [EB/OL ] .( 2024-08-05 )[ 2025-12-01 ] . https://training.cochrane.org/handbook https://training.cochrane.org/handbook .
STANG A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses [J ] . Eur J Epidemiol , 2010 , 25 ( 9 ): 603 - 605 .
ONG E G P , EATON S , WADE A M , et al . Randomized clinical trial of glutamine-supplemented versus standard parenteral nutrition in infants with surgical gastrointestinal disease [J ] . Br J Surg , 2012 , 99 ( 7 ): 929 - 938 .
CHAUDHRY K K , SHUKLA P K , MIR H , et al . Glutamine supplementation attenuates ethanol-induced disruption of apical junctional complexes in colonic epithelium and ameliorates gut barrier dysfunction and fatty liver in mice [J ] . J Nutr Biochem , 2016 , 27 : 16 - 26 .